Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scot C Remick

Showing results (51-60 of 93) with videos related to

Pageof 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2010
Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumorsRamesh K Ramanathan, Merrill J Egorin, Charles Erlichman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2004
Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancerMatthew M Cooney, Tomas Radivoyevitch, Afshin Dowlati, et al.
Cardiovascular Journal of Africa|May 11, 2018
Stroke distribution patterns and characteristics in Kenya's leading public health tertiary institutions: Kenyatta National Hospital and Moi Teaching and Referral HospitalLydia Kaduka, Anne Korir, Chrispine Owuor Oduor, et al.
World Journal of Urology|August 29, 2018
Prostate cancer navigation: initial experience and association with time to careEmily C Serrell, Moritz Hansen, Greg Mills, et al.
Investigational New Drugs|September 24, 2009
A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumorsCharles J Nock, Joanna M Brell, Joseph A Bokar, et al.
American Journal of Hematology|June 19, 2009
Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplantPaul M Barr, Hillard M Lazarus, Brenda W Cooper, et al.
Cancer Chemotherapy and Pharmacology|August 2, 2008
A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinomaJoanna M Brell, Smitha S Krishnamurthi, Milind Javle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
Novel Phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416Afshin Dowlati, Kelly Robertson, Tomas Radivoyevitch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2008
Confirmation of gene expression-based prediction of survival in non-small cell lung cancerNancy L Guo, Ying-Wooi Wan, Kursad Tosun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2003
Phase I and correlative study of combination bryostatin 1 and vincristine in relapsed B-cell malignanciesAfshin Dowlati, Hillard M Lazarus, Paul Hartman, et al.
Pageof 10

Showing results (51-60 of 93) with videos related to

Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2010
Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumorsRamesh K Ramanathan, Merrill J Egorin, Charles Erlichman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2004
Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancerMatthew M Cooney, Tomas Radivoyevitch, Afshin Dowlati, et al.
Cardiovascular Journal of Africa|May 11, 2018
Stroke distribution patterns and characteristics in Kenya's leading public health tertiary institutions: Kenyatta National Hospital and Moi Teaching and Referral HospitalLydia Kaduka, Anne Korir, Chrispine Owuor Oduor, et al.
World Journal of Urology|August 29, 2018
Prostate cancer navigation: initial experience and association with time to careEmily C Serrell, Moritz Hansen, Greg Mills, et al.
Investigational New Drugs|September 24, 2009
A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumorsCharles J Nock, Joanna M Brell, Joseph A Bokar, et al.
American Journal of Hematology|June 19, 2009
Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplantPaul M Barr, Hillard M Lazarus, Brenda W Cooper, et al.
Cancer Chemotherapy and Pharmacology|August 2, 2008
A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinomaJoanna M Brell, Smitha S Krishnamurthi, Milind Javle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
Novel Phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416Afshin Dowlati, Kelly Robertson, Tomas Radivoyevitch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2008
Confirmation of gene expression-based prediction of survival in non-small cell lung cancerNancy L Guo, Ying-Wooi Wan, Kursad Tosun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2003
Phase I and correlative study of combination bryostatin 1 and vincristine in relapsed B-cell malignanciesAfshin Dowlati, Hillard M Lazarus, Paul Hartman, et al.
Pageof 10